Clinical trial
Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings
NCT05366257 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Real-world Resource Use and Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma (DLBCL): Inpatient and Outpatient Settings
- Lead sponsor
- Novartis Pharmaceuticals
- Phase
- Observational
- Overall status
- Completed
- Start date
- August 17, 2020
- Completion date
- May 10, 2021
- Enrollment
- Not reported
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
diffuse large b-cell lymphoma (dlbcl)